Literature DB >> 23959916

Medication assessment tool to detect care issues from routine data: a pilot study in primary care.

Tobias Dreischulte, Julienne Johnson, John McAnaw, Marlies Geurts, Han de Gier, Steve Hudson.   

Abstract

BACKGROUND: Medication assessment tools (MATs) may be implemented in routine electronic data sources in order to identify patients with opportunities for optimisation of medication therapy management (MTM) and follow-up by a multi-disciplinary team.
OBJECTIVE: (1) To demonstrate the use of a MAT for cardiovascular conditions (MAT CVC) as a means of profiling potential opportunities for MTM optimisation in primary care and (2) to assess the performance of MAT CVC in identifying actual opportunities for better care.
SETTING: Members of a pharmacotherapy discussion group, i.e. two single-handed general practitioners (GPs), three GP partners, and community pharmacists (CPs) from each of two community pharmacies, in a rural part of the Netherlands.
METHODS: MAT CVC comprises 21 medication assessment criteria, each of which is designed to detect a specific care issue and to check whether it is 'addressed' by provision of guideline recommended care or 'open' in the presence ('open explained') or absence ('open unexplained') of pre-specified explanations for guideline deviations. (1) Relevant data was extracted from linked GP and CP electronic records and MAT CVC assessment was conducted to profile the population of CVC patients registered with both, participating CPs and GPs, in terms of 'open unexplained' care issues. (2) A purposive sample of patients with 'open unexplained' care issues was reviewed by each patient's GP. MAIN OUTCOME MEASURES: Number and proportion of 'open unexplained' care issues per MAT CVC criterion and per patient. The number of patients with MAT CVC detected 'open unexplained' care issues to be reviewed (NNR) in order to identify one that requires changes in MTM.
RESULTS: In 1,876 target group patients, MAT CVC identified 6,915 care issues, of which 2,770 (40.1 %) were 'open unexplained'. At population level, ten MAT CVC criteria had particularly high potential for quality improvement. At patient level, 1,277 (68.1 %) target group patients had at least one 'open unexplained' care issue. For patients with four or more 'open unexplained' care issues, the NNR was 2 (95 % CI 2-2).
CONCLUSION: The study demonstrates potential ways of using MA TCVC as a key component of a collaborative MTM system. Strategies that promote documentation and sharing of explanations for deviating from guideline recommendations may enhance the utility of the approach.

Entities:  

Mesh:

Year:  2013        PMID: 23959916     DOI: 10.1007/s11096-013-9828-2

Source DB:  PubMed          Journal:  Int J Clin Pharm


  43 in total

Review 1.  The role of patient care teams in chronic disease management.

Authors:  E H Wagner
Journal:  BMJ       Date:  2000-02-26

2.  European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts).

Authors:  Ian Graham; Dan Atar; Knut Borch-Johnsen; Gudrun Boysen; Gunilla Burell; Renata Cifkova; Jean Dallongeville; Guy De Backer; Shah Ebrahim; Bjørn Gjelsvik; Christoph Herrmann-Lingen; Arno Hoes; Steve Humphries; Mike Knapton; Joep Perk; Silvia G Priori; Kalevi Pyorala; Zeljko Reiner; Luis Ruilope; Susana Sans-Menendez; Wilma Scholte Op Reimer; Peter Weissberg; David Wood; John Yarnell; Jose Luis Zamorano; Edmond Walma; Tony Fitzgerald; Marie Therese Cooney; Alexandra Dudina; Alec Vahanian; John Camm; Raffaele De Caterina; Veronica Dean; Kenneth Dickstein; Christian Funck-Brentano; Gerasimos Filippatos; Irene Hellemans; Steen Dalby Kristensen; Keith McGregor; Udo Sechtem; Sigmund Silber; Michal Tendera; Petr Widimsky; Jóse Luis Zamorano; Attila Altiner; Enzo Bonora; Paul N Durrington; Robert Fagard; Simona Giampaoli; Harry Hemingway; Jan Hakansson; Sverre Erik Kjeldsen; mogens Lytken Larsen; Giuseppe Mancia; Athanasios J Manolis; Kristina Orth-Gomer; Terje Pedersen; Mike Rayner; Lars Ryden; Mario Sammut; Neil Schneiderman; Anton F Stalenhoef; Lale Tokgözoglu; Olov Wiklund; Antonis Zampelas
Journal:  Eur J Cardiovasc Prev Rehabil       Date:  2007-09

3.  Polypharmacy and the balance of medication benefits and risks.

Authors:  Michael A Steinman
Journal:  Am J Geriatr Pharmacother       Date:  2007-12

4.  Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation.

Authors:  Robby Nieuwlaat; Alessandro Capucci; Gregory Y H Lip; S Bertil Olsson; Martin H Prins; Fred H Nieman; José López-Sendón; Panos E Vardas; Etienne Aliot; Massimo Santini; Harry J G M Crijns
Journal:  Eur Heart J       Date:  2006-05-26       Impact factor: 29.983

5.  An evaluation of community pharmacy records in the development of pharmaceutical care in The Netherlands.

Authors:  H Rahimtoola; A Timmers; R Dessing; S Hudson
Journal:  Pharm World Sci       Date:  1997-04

6.  Design and validation of a medication assessment tool for cancer pain management.

Authors:  Gro Dahlseng Håkonsen; Steve Hudson; Thrina Loennechen
Journal:  Pharm World Sci       Date:  2006-11-21

7.  Causes of preventable drug-related hospital admissions: a qualitative study.

Authors:  R Howard; A Avery; P Bissell
Journal:  Qual Saf Health Care       Date:  2008-04

8.  Reasons for not intensifying medications: differentiating "clinical inertia" from appropriate care.

Authors:  Monika M Safford; Richard Shewchuk; Haiyan Qu; Jessica H Williams; Carlos A Estrada; Fernando Ovalle; Jeroan J Allison
Journal:  J Gen Intern Med       Date:  2007-10-24       Impact factor: 5.128

9.  Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States.

Authors:  Katharina Wolf-Maier; Richard S Cooper; José R Banegas; Simona Giampaoli; Hans-Werner Hense; Michel Joffres; Mika Kastarinen; Neil Poulter; Paola Primatesta; Fernando Rodríguez-Artalejo; Birgitta Stegmayr; Michael Thamm; Jaakko Tuomilehto; Diego Vanuzzo; Fenicia Vescio
Journal:  JAMA       Date:  2003-05-14       Impact factor: 56.272

10.  Adherence to clinical guidelines in the prevention of coronary heart disease in type II diabetes mellitus.

Authors:  Majidreza Kamyar; B Julienne Johnson; John J McAnaw; Rosa Lemmens-Gruber; Steve A Hudson
Journal:  Pharm World Sci       Date:  2007-08-25
View more
  3 in total

1.  Assessing appropriateness of drug therapy in older persons: Development and application of a medication assessment tool for long-term management of atrial fibrillation.

Authors:  Marise Gauci; Francesca Wirth; Liberato Camilleri; Lilian M Azzopardi; Anthony Serracino-Inglott
Journal:  Pharm Pract (Granada)       Date:  2017-12-18

2.  Development and validation of medication assessment tools to evaluate prescribing adherence to evidence-based guidelines for secondary prevention of coronary heart disease in post-acute coronary syndromes patients in Kuwait.

Authors:  Dalal Al-Taweel; Abdelmoneim Awad
Journal:  PLoS One       Date:  2020-11-30       Impact factor: 3.240

3.  Developing a complex intervention to improve prescribing safety in primary care: mixed methods feasibility and optimisation pilot study.

Authors:  Aileen M Grant; Bruce Guthrie; Tobias Dreischulte
Journal:  BMJ Open       Date:  2014-01-21       Impact factor: 2.692

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.